Last updated: March 18, 2026
What is the current market size for Pregabalin?
Pregabalin, marketed as Lyrica by Pfizer, generated approximately $3.4 billion in global sales in 2022. The drug primarily targets neuropathic pain, epilepsy, and generalized anxiety disorder.
| Region |
2022 Sales |
Market Share (%) |
Key Competitors |
| United States |
$1.8 billion |
53 |
Gabapentin, Eslicarbazepine |
| Europe |
$800 million |
24 |
Gabapentin, Duloxetine |
| Asia-Pacific |
$600 million |
18 |
Generic formulations |
| Rest of World |
$200 million |
5 |
Local generics |
How does the patent landscape influence the market?
Pfizer’s original patent for Pregabalin expires in the US in 2018, with subsequent patents for formulations expiring into the early 2020s. Patent expirations have led to a surge of generic versions, reducing prices and market share for branded Lyrica.
- US Pfizer patent expiry: 2018
- US generics entry: 2019–2020
- Market decline for branded Lyrica: 10–15% annually after patent expiry
- EU patent expiry: 2019 for certain formulations
What are the key drivers of market growth?
Market growth for Pregabalin hinges on several factors:
- Unmet needs in neuropathic pain, especially diabetic peripheral neuropathy
- Off-label uses, such as social anxiety disorder
- Expanded indications approved in some countries, like postherpetic neuralgia
- Increasing prevalence of chronic pain and epilepsy globally
How are market players responding?
Major pharmaceutical companies are shifting toward generics, biosimilars, or alternative therapies:
- Pfizer's exit from gig markets in certain regions
- Development of extended-release and combination formulations
- Investment in pipeline drugs for similar indications, e.g., gabapentin derivatives
- Focus on markets with patent protection, such as Japan and emerging economies
What is the outlook for regulatory and reimbursement policies?
Regulatory agencies impact market trajectory through patent protections, approvals, and reimbursement policies. Key points:
- US FDA's approval processes: fast-track options for new formulations
- European regulations favor generic substitution post-patent expiry
- Reimbursement reductions in some regions due to cost-containment efforts
- Increasing scrutiny of off-label prescribing impacting sales
What are the financial projections for Pregabalin?
Forecasts indicate declining revenues in main markets due to generics. But growth in emerging markets and off-label use may counteract some decline.
| Year |
Projected Global Sales |
CAGR (2023–2027) |
Notes |
| 2023 |
$2.8 billion |
-5% |
Post-patent expiry decline |
| 2025 |
$2.5 billion |
-7% annually |
Continued generic penetration |
| 2027 |
$2.2 billion |
|
Potential stabilizers in emerging markets |
How do generic formulations affect overall market revenue?
Generic versions have driven prices down by 50–70%, leading to substantial revenue loss for originator companies. The entry of biosimilar-like formulations or novel delivery mechanisms may offer new revenue streams, but their impact remains limited in the immediate term.
Summary
Pregabalin faces a mature market with declining revenues in developed countries due to patent expiration and generic competition. Growth opportunities concentrate in emerging markets and off-label therapeutic uses. Competitive strategies include formulation innovation and pipeline development. Regulatory and reimbursement policies significantly influence future market dynamics.
Key Takeaways
- Global sales declined from peak over $3.4 billion in 2022 due to patent expiries.
- Generic competition has reduced average prices by over 50%.
- Market growth prospects shift toward emerging economies and off-label uses.
- Patent expirations in key markets have prompted strategic shifts among manufacturers.
- New formulation development and pipeline drugs aim to sustain revenue streams.
FAQs
1. When did Pregabalin lose patent protection in the US?
Pfizer’s primary patent for Pregabalin expired in 2018, leading to widespread generic entry starting in 2019.
2. How much revenue has Pfizer lost due to generics?
Pfizer's branded sales declined by approximately 70% post-2018 patent expiry, accounting for billions in revenue loss.
3. Are there new formulations of Pregabalin being developed?
Yes; companies are exploring extended-release versions and combination therapies to differentiate products and extend market life.
4. What are the main off-label uses impacting sales?
Chronic pain, social anxiety disorder, and other neurological conditions contribute to off-label prescribing.
5. How do reimbursement policies affect Pregabalin markets?
Reimbursement reductions in certain regions decrease formulary inclusion, impacting sales volume and pricing strategies.
Sources
- Pfizer Inc. (2023). Lyrica sales report.
- IQVIA. (2022). Global pharmaceutical market analysis.
- U.S. Food and Drug Administration. (2018). Patent expiration notices.
- European Medicines Agency. (2019). Regulatory updates on Pregabalin.
- GlobalData. (2023). Market forecasts for neuropathic pain therapies.
